Latest Ratios: P/E Ratio 0.0x · EV/EBITDA N/A · ROE N/A. (2021–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $5807 | $43414 | — | — | — |
| Enterprise Value | $10M | $10M | — | — | — |
| P/E Ratio → | 0.00 | — | — | — | — |
| P/S Ratio | 0.00 | 0.03 | — | — | — |
| P/B Ratio | — | — | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | 7.08 | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | -6.8% | -6.8% | -40.8% | -112.1% | -188.5% |
| Operating Margin | -3030.4% | -3030.4% | -1006.5% | -15332.1% | -13520.3% |
| Net Profit Margin | -4762.8% | -4762.8% | -1677.4% | -14942.5% | -12623.9% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | — | — | — | — | — |
| ROA | -358.3% | -358.3% | -113.1% | -56.6% | -36.7% |
| ROIC | — | — | — | — | — |
| ROCE | -3500.9% | -3500.9% | -100.0% | -62.7% | -42.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | -42.48 | -42.48 | -15.48 | -55.57 | -4.85 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | 1.28 | 1.28 | 0.17 | 4.72 | 7.79 |
| Quick Ratio | 1.28 | 1.28 | 0.17 | 4.72 | 7.79 |
| Cash Ratio | 0.51 | 0.51 | 0.03 | 4.14 | 7.11 |
| Asset Turnover | — | 0.11 | 0.14 | 0.00 | 0.00 |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — | — |
| Shares Outstanding | — | $789338 | $789338 | $789338 | $789338 |
Imminent Liquidity and Solvency
As reported in recent financial statements, BSLKW's ROIC of -154.6% in 2025Q1 underscores a severe inability to generate returns on invested capital, suggesting that the company's heavy reliance on R&D and pilot-scale infrastructure is currently failing to create any meaningful economic value for shareholders.
The deeply negative ROIC indicates that every dollar invested into the business is currently eroding rather than compounding. This trend suggests that the company's core bio-material platform has yet to achieve the necessary scale or cost-efficiency to justify its capital intensity.
Based on the company's reported figures, the asset turnover ratio has remained negligible, hovering near 0.04 in 2025Q3, which highlights a fundamental disconnect between the firm's asset base and its ability to generate revenue from its proprietary bio-engineered protein sequences.
The extremely low asset turnover suggests that the company's physical and intellectual assets are largely underutilized or currently unproductive. Investors should monitor whether this reflects a strategic pivot away from internal manufacturing or simply an inability to secure sufficient commercial demand for its products.
According to recent SEC filings, the current ratio has deteriorated to 0.69 as of 2025Q3, indicating that the company's short-term assets are insufficient to cover its immediate liabilities, thereby raising significant concerns regarding its ability to continue as a going concern without external intervention.
The decline in liquidity ratios suggests that the company is rapidly exhausting its financial runway. This position leaves the firm highly vulnerable to any operational disruptions or delays in securing additional capital, as there is little margin for error in its current cash management strategy.
As disclosed in financial statements, the market's reliance on EV/Revenue multiples for BSLKW is fundamentally flawed, as the company's current revenue of $1.37M is not a reflection of a stable business model but rather a collection of sporadic, non-recurring R&D-linked payments.
Using revenue multiples for a pre-scale entity like BSLKW obscures the reality that the company is essentially a research-stage venture rather than a commercial enterprise. Analysts should instead focus on cash burn rates and the cost of achieving specific fermentation yield milestones to assess the company's true viability.
Includes 30+ ratios · 4 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BSLKW stock.
Bolt Projects Holdings, Inc.'s current P/E ratio is 0.0x.
Based on historical data, Bolt Projects Holdings, Inc. is trading at valuation metrics that vary. Compare with industry peers and growth rates for a complete picture.
Bolt Projects Holdings, Inc. has -6.8% gross margin and -3030.4% operating margin.